Form 4: Cytek Biosciences Director Acquires 15,706 Shares Through RSU Vesting
Insider Transaction Report
Don M. Hardison, a Director at Cytek Biosciences, Inc., has acquired 15,706 shares of common stock following the vesting of Restricted Stock Units on June 5, 2025.
Summary
- Don M. Hardison, a Director of Cytek Biosciences, Inc. (CTKB), acquired 15,706 shares of the company's common stock.
- The acquisition resulted from the vesting of Restricted Stock Units (RSU Award) on June 5, 2025.
- Each RSU represents a contingent right to receive one share of the Issuer's common stock.
- 100% of the shares subject to the RSU Award vested on June 5, 2025.
- Following this transaction, Mr. Hardison directly beneficially owns 15,706 shares of common stock.
Sentiment
Score: 6
Explanation: The sentiment is neutral to slightly positive. While a routine compensation event, it signifies a director's continued equity stake in the company, which can be seen as a positive alignment of interests. There are no negative implications from this specific transaction.
Positives
- The vesting of Restricted Stock Units for a director indicates a planned compensation event, aligning management's interests with shareholders through equity ownership.
Future Outlook
This Form 4 filing does not contain any forward-looking statements or guidance regarding the company's future outlook.
Industry Context
This filing is a routine insider transaction report, common across all industries, reflecting a director's equity compensation vesting. It does not provide specific insights into broader industry trends for the biotechnology or life sciences sector.
Stakeholder Impact
- Shareholders: The vesting of RSUs and subsequent acquisition of shares by a director aligns the director's financial interests with those of the shareholders, potentially fostering long-term value creation. This is a routine compensation event and does not imply significant dilution.
Key Dates
| Date | Description |
|---|---|
| 06/05/2025 | Date of earliest transaction; 100% vesting of Restricted Stock Units (RSU Award) and acquisition of common stock. |
| 06/09/2025 | Date the Form 4 was signed by the attorney-in-fact for the reporting person. |
Keywords
Cytek Biosciences, CTKB, Form 4, Insider Transaction, Restricted Stock Units, RSU, Stock Vesting, Director Stock Acquisition, Don M. Hardison, Equity Compensation
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.